Siligmueller & Norvid Wealth Advisors LLC Makes New Investment in AbbVie Inc. $ABBV

Siligmueller & Norvid Wealth Advisors LLC acquired a new position in shares of AbbVie Inc. (NYSE:ABBV) during the third quarter, HoldingsChannel reports. The institutional investor acquired 12,436 shares of the company’s stock, valued at approximately $2,879,000. AbbVie accounts for approximately 1.3% of Siligmueller & Norvid Wealth Advisors LLC’s investment portfolio, making the stock its 25th largest position.

Other large investors have also modified their holdings of the company. Diversified Trust Co boosted its stake in shares of AbbVie by 23.6% during the third quarter. Diversified Trust Co now owns 57,076 shares of the company’s stock valued at $13,215,000 after acquiring an additional 10,891 shares during the last quarter. Permanent Capital Management LP purchased a new position in AbbVie in the 3rd quarter valued at about $720,000. Railway Pension Investments Ltd boosted its stake in shares of AbbVie by 33.0% during the 3rd quarter. Railway Pension Investments Ltd now owns 853,949 shares of the company’s stock worth $197,723,000 after purchasing an additional 211,800 shares during the last quarter. World Investment Advisors grew its holdings in shares of AbbVie by 9.4% during the third quarter. World Investment Advisors now owns 113,925 shares of the company’s stock worth $26,378,000 after buying an additional 9,811 shares in the last quarter. Finally, Charles Schwab Trust Co grew its holdings in shares of AbbVie by 93.4% during the third quarter. Charles Schwab Trust Co now owns 32,105 shares of the company’s stock worth $7,434,000 after buying an additional 15,502 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Trading Up 0.3%

ABBV stock opened at $224.94 on Friday. The company has a market cap of $397.56 billion, a PE ratio of 95.31, a price-to-earnings-growth ratio of 0.78 and a beta of 0.35. The stock has a 50-day moving average price of $224.04 and a two-hundred day moving average price of $221.89. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating the consensus estimate of $2.65 by $0.06. AbbVie had a negative return on equity of 4,184.47% and a net margin of 6.91%.The business had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. During the same period in the previous year, the company posted $2.16 EPS. The company’s revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Equities analysts forecast that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 3.1%. The ex-dividend date is Wednesday, April 15th. AbbVie’s dividend payout ratio is currently 293.22%.

Analyst Ratings Changes

A number of analysts recently issued reports on ABBV shares. Citigroup decreased their target price on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 27th. DZ Bank cut AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price objective on the stock. in a report on Tuesday, November 4th. Evercore lowered their price objective on AbbVie from $232.00 to $228.00 and set an “outperform” rating for the company in a research report on Wednesday, February 4th. Piper Sandler increased their target price on AbbVie from $289.00 to $299.00 and gave the stock an “overweight” rating in a research report on Wednesday. Finally, UBS Group decreased their price target on AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a research note on Thursday, February 5th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, AbbVie currently has an average rating of “Moderate Buy” and a consensus target price of $252.79.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: FDA approved the VENCLEXTA® (venetoclax) + acalabrutinib combination for previously untreated chronic lymphocytic leukemia (CLL). This is the first all‑oral, fixed‑duration combo for this setting, supported by Phase 3 AMPLIFY data—it can meaningfully expand uptake for Venclexta and acalabrutinib, strengthen AbbVie’s oncology franchise and offer a durable revenue stream versus one‑off treatments. U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
• Positive Sentiment: Industry write‑ups frame the FDA approval as a potential new standard for a slow‑growing blood cancer, highlighting better three‑year outcomes and the “time off therapy” selling point—this can accelerate physician adoption and market share vs. chemo regimens. FDA Approval For AbbVie/AstraZeneca’s Combination Treatment Could Set New Standard For Slow Growing Blood Cancer
• Positive Sentiment: AbbVie opened a Phase 2a study for ABBV‑142 in idiopathic pulmonary fibrosis (IPF), broadening its respiratory/pulmonary pipeline beyond core immunology and oncology programs. Early‑stage pipeline depth helps investor sentiment around post‑Humira growth optionality. AbbVie Expands IPF Pipeline With New Phase 2a Study of ABBV-142
• Positive Sentiment: Board declared a $1.73 quarterly dividend (yield ~3.1%), reinforcing the income profile for dividend‑focused investors and supporting the stock’s defensive appeal. Dividend cadence and yield matter for total return expectations. AbbVie Declares Quarterly Dividend
• Neutral Sentiment: Quarterly results and commentary show Rinvoq and Skyrizi continuing to drive top‑line growth and offset Humira erosion; that underpins management’s guidance but much of these dynamics are already reflected in recent estimates. Will Immunology Drugs Continue to Drive AbbVie’s Top Line in 2026?
• Neutral Sentiment: Coverage pieces ask whether AbbVie’s post‑Humira pipeline merits renewed investor attention — useful for narrative, but these are discussion pieces rather than new data that would immediately re‑rate the stock. Should AbbVie’s (ABBV) Post-Humira Pipeline Progress Prompt a Fresh Look From Investors?
• Neutral Sentiment: Marketing/PR items (new podcast, inclusion in dividend lists, media mentions) help brand and investor awareness but are unlikely to move fundamentals in the near term. AbbVie heads to ‘The Persistence Lab’ in new podcast highlighting healthcare innovation
• Negative Sentiment: Evercore noted Tremfya’s share gains but flagged possible limits to future earnings growth and trimmed its price target slightly—this is a modest analyst headwind that could cap upside if more firms follow with tepid updates. Evercore Notes AbbVie Inc.’s (ABBV) Tremfya Gains Market Share, But Future Earnings Growth May Be Limited

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.